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ABSTRACT 
 
Background: Invasive ductal carcinoma is the most common type of breast cancer in Iran. Im-
paired immune responses occur frequently in cancer patients, but the mechanisms of the induced 
immune defects remain poorly understood. It is believed that infiltrated immune cells, especially 
macrophages, may provide help for tumor cell growth and metastasis. Objective: To analyze the 
status of tumor associated macrophages (TAM) by immunophenotyping method. Methods: 
Twenty-three women suffering from breast cancer were examined; nineteen of them were con-
firmed histologically to have invasive ductal carcinoma. Tumor cell suspensions from biopsy 
specimens and peripheral blood mononuclear cells from patients and matched controls were 
processed for analysis by flow cytometry. Results: No significant changes in the percentages of 
intra-tumor leukocytes and macrophages in the different stages of tumor were observed. There 
were no significant differences in the percentages of leukocytes (CD45+), monocytes 
(CD45+/CD14+) and activated monocytes (CD14+/HLA-DR+ and CD14+/CD16+) in the periph-
eral blood of patients and controls. Conclusion: The results of this study indicated that human 
breast cancer contain substantial, although variable numbers of macrophages, however, the acti-
vation status of these macrophages remain to be elucidated. 
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INTRODUCTION 
 
Invasive ductal carcinoma is the most common type of breast cancer in Iran. Impaired im-
mune responses occur frequently in cancer patients, but the mechanisms of the induced im-
mune defects remain poorly understood (1). In many carcinomas, infiltrating macrophages are 
commonly found closely associated with tumor but little is known concerning the nature or 
significance of adherent molecules in these cellular interactions (2). In addition, the presence 
of immature dendritic cells within the tumor has been reported, whereas mature dendritic cells 
are located in peri-tumoral area (3). 
In many solid tumors the abundance of tumor-associated macrophages (TAMs) is correlated 
with poor prognosis (4). Current evidence suggests that in established, progressively growing 
solid tumors, TAMs are reprogrammed to induce immune suppression of host defenses in situ, 
through release of specific cytokines, prostanoids and other humoral mediators. This disor-
dered response, results in the inhibition of effective anti-cancer cell-mediated immune 
mechanisms. Concurrently, TAMs produce tumor growth promoting factors (5). Other studies 
have shown that macrophage expression urokinase (uPA) plays a key role in the degradation 
of tumor matrix and promotes tumor progression (6). 
 The summation of this complex interplay of biological factors results in progressive tumor 
growth and tumor cell dissemination. A better understanding of these complex inter-
relationships should form the basis of novel strategies to eradicate tumor cells in man and 
animals. Previous studies suggested the production of cytokines as a significant parameter in 
the regulation of tumor prognosis and indicated a defect in IL-12 production capability while 
generating higher amounts of IL-10 (7). 
In this study we aimed to measure the percentage of macrophages infiltrated in tumor by 
flowcytometer, and estimate the activity of these cells in different stages of breast tumors. 
 
 
MATERIAL AND METHODS 
 
Patients. Twenty-three patients with breast cancer who underwent surgical procedure were 
studied in Cancer Institute of Imam-Khomeini hospital, Tehran. Patients with a history of 
chemotherapy and/or radiotherapy were excluded from study. The age of patients ranged from 
26-70 yr (mean 45.4). Nineteen of the patients were diagnosed pathologically to have invasive 
ductal carcinoma (82.6%), two of the patients had invasive lobular carcinoma (8.7%), one pa-
tient had ductal carcinoma in situ, one patient had atypical modularly carcinoma and one pa-
tient had fibrocystic breast disease. Peripheral blood of nine cancer patients and 9 matched 
control women were collected in EDTA-coated tubes. The mononuclear cell fraction of blood 
samples were isolated by ficole and processed for immunostaining (see below). The patients 
and controls participated in this study after informed consent.  
Preparation of Tumor Cell Suspension. Biopsies of human solid tumor were cut into small 
pieces with forceps and scalpel. The pieces were rinsed twice with phosphate buffer saline, 
then 5 ml of cocktail enzymes (0.05 mg/ml collagenase and 0.002 mg/ml DNAse) were 
added and the mixture was placed in 37oC for 2-4 hrs. The suspension was passed through 
150-micron stainless steel mesh. Cells were washed twice and labeled with monoclonal an-
tibodies. 
Immunophenotyping. The following fluorescent monoclonal antibodies (mAb) were used 
to identify leukocytes and TAM in both PBL and tumor cell suspensions: anti-CD45 for de-
tection of leukocytes, anti-CD45/CD14 for detection of monocyte/macrophages and both 
anti-CD14/CD16 and anti-CD14/HLA-DR for detection of activated mono-
cyte/macrophages (8). We established the reference immunophenotypic pattern using stan-
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dard procedures. In this study 100µl of each blood sample was treated as follows; each sam-
ple was immunostained with 10µl of each mAbs directly conjugated with Fluorescein 
Isothiocyanate (FITC) or R-Phycoerythrin (RPE). Each sample was then fixed with para-
formaldehyed and kept in 2-8 oC and dark for about 24 hrs (8). 
Flowcytometric Analysis. Cell sample were measured on a coulter flowcytometer with serial 
filter configuration. The analysis was focused on the myeloid areas of the forward and side 
scatters. Double stained cells were analyzed using coulter software. 
Statistical Analysis. One-way analysis of variation (ANOVA) and Kruskal-Wallis nonpara-
metric test were employed using SPSS software. 
 
 
RESULTS 
 
Comparison of PBL monocytes between breast cancer patients and controls 
Table 1 summarized the percentages of PBL leukocytes and monocytes in both patients and 
control group. Flowcytometric analysis was done in the gate of monocyte. Results indicated 
no significant differences in the percentage of leukocytes and monocytes compared to the 
control group. 
The percentage of CD16+ cells showed significant differences between two groups (P = 
0.007) and the number of these cells showed a significant decrease in breast cancer patients.  
 
Table1. Flowcytometric analysis of leukocytes and monocytes in peripheral 
blood of breast cancer patients and control group 
                                                  
CD                                                          Breast Cancer                                       Control                                                       P value 
                                                                (n = 9)                                                     (n = 9) 
Marker                     
 
CD45+ a                                                    88.5                                                          92.5                                                         0.2 
CD45+/CD14+                                          2                                                              3.1                                                            0.44 
CD45+/CD14+          × 100                           2.7                                                           3.4                                                            0.44 
    CD45+                                        
 
CD16+                                                    19.7                                                          54.2                                                          0.007 
CD14+/CD16+                                        0.4                                                            0.9                                                            0.1 
CD14+/CD16+        × 100                       0.4                                                            1                                                               0.1 
     CD45+ 
 
HLA-DR+                                                                           8.4                                                           6.6                                                            0.3 
D14+/HLA-DR+                                                           0.6                                                            0.7                                                            0.44 
D14+/HLA-DR+       × 100                      0.6                                                            0.8                                                            0.44 
      CD45+ 
 
a values  are shown in mean percentages and analysis was done in monocyte gate 
 
Percentage of Tumor Associated Macrophages. In order to evaluate the percent of intratu-
mor TAM, 23 patients were divided into two groups (IDC group and ILC+DCI+AMC group). 
The normal or benign tissues were considered as group 3. All the data was analyzed in the 
leukocyte gate. As shown in Table 2 the mean percentage of intratumor CD14+/HLA-DR+ 
cells were significantly (P = 0.03) higher in control group compared with breast cancer groups 
(group 1 and 2). 
Correlation between TAM and Clinical Staging of Tumor. In order to assess the correla-
tion between the percentage and activity of peripheral blood monocytes and TAM in differ-
ent stages of tumor, patients having stages 1, 2 and 3 of the disease were evaluated. Results 
in table 3 indicated no significant differences between different stages of tumor. The CD45+, 
CD 14+/CD16+ and CD14+/HLA-DR+ cells decreased remarkably in stage II of breast cancer 
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and in the cases of CD45+ and CD14+/HLA-DR+ cells, this decrease was considerable but sta-
tistically insignificant (Table3). 
 
Table 2. Imunostatus of tumor associated macrophages in breast cancer patients 
 
                                               Group 1                                            Group 2                                       Group 3                                      
Marker                                         (n =19)                                              (n = 4)                                           (n = 3)                               P value 
                                                      IDC*                                                 ILC+DCI+AMC*                       Benign/control  
 
CD45+                                          16.4                                                    19.53                                            12.85                                    0.9 
CD45+/CD14+                              2.64                                                    1.86                                              3.72                                      0.4   
CD45+/CD14+         ×100                24.49                                                  30.37                                            33.77                                    0.8 
    CD45+                              
 
CD16+                                                        17.18                                                   6.6                                                11.7                                      0.5 
CD14+/CD16+                            1.56                                                     1.38                                              1.6                                         0.96 
CD14+/CD16+     ×100               12.3                                                     27.18                                            11.07                                     0.3 
    CD45+ 
 
HLA-DR+                                                       14.71                                                 11.18                                              19.5                                       0.4 
CD14+/HLA-DR+                      1.57                                                   1.23                                                 3.03                                      0.03 
D14+/HLA-DR+       ×100          13.62                                                 14.42                                               16.65                                     0.35 
   CD45+            
 
*IDC = Invasive ductal carcinoma; ILC = Invasive lobular carcinoma; DCI = Ductal carcinoma in situ; AMC = Atypical modularly carci-
noma 
 
In another analysis, the sizes of tumors correlated with the status of leukocytes and TAM.  
Results in Table 4 indicated no significant decrease in the total leukocyte and TAM count 
when the tumor size increased. 
 
 
Table 3. Immunostatus of monocyte/macrophages in different stages of Invasive 
ductal carcinoma patientsa 
                                 
  CD  Marker                                                 PBL  cells                                                                         Intratumor   cells       
                                               stages:   I               II               III              P Value                stages:   I              II                 III              P Value 
  
CD45 +                                                88.25        94.57          82.57             0.2                                  14            9.18            28.9              0.07 
CD45+/CD14+                                    1.97           2.24            1.85               0.9                                  2.78         1.95            3.57              0.25  
CD14+/CD16+                                    0.3             0.25            0.4                 0.6                                  2.77          0.65           2.05              0.06 
CD14+/HLA-DR+                              0.63           0.43             0.63              0.8                                  2.33          1.23           1.5                 0.35  
 
a The minimum number of cases used in each stage of tumor was three 
 
 
 
Table 4. Imunostatus of monocyte/macrophages in Invasive ductal carcinoma tumors 
with different sizesa 
 
                                                                                                   
CD Marker                                                         Intratumor                                                                          Cells      
                                                           <2cm                                  2-3cm                                   >3cm                                      P Value 
 
CD45+                                                 19.6                                    9.8                                           19                                        0.6 
CD45+/CD14+                                      2.8                                     2.8                                           2.3                                       0.9 
CD14+/CD16+                                      2.2                                     1.2                                           0.9                                       0.3 
CD14+/HLA-DR+                                1.5                                      0.9                                          1.9                                       0.5 
 
cm= centimeter 
a The minimum number of cases used in each stage of tumor was three 
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DISCUSSION 
 
The immune system is capable of responding to cancer as evidenced by systemic, regional, 
and intratumoral leukocyte activation. For individual patients there is no predictable relation-
ship between leukocyte composition, or function, and the prognosis of the disease (9). 
Immunohistological analysis of tissue sections and isolation of cells by mechanical desegrega-
tion and enzymatic digestion of excised tumors are the established methods used to study the 
cell composition of tumors (10). Previous published studies indicated that the number of 
macrophages is substantial but varies greatly among the different studied tumors (11,12). 
Macrophages also infiltrate metastatic lesions, although TAMs have been less extensively 
studied in secondary tumor deposits (13).    
The Results of our study indicated that CD16+ bearing cells significantly decrease in the PBL 
of breast cancer patients (Table 1). In the PBL population of human activated monocytes and 
natural killer (NK) cells express CD16 marker, therefore it is reasonable to assume a signifi-
cant decrease of these two important cell populations in our patients. 
We also evaluated the presence of macrophages within the invasive ductal carcinoma and 
other tumors of breast compared to fibrocystic benign tumor. The range of infiltrated CD45+ 
cells was variable (2.7 and up to 61.7). The range of infiltrated CD14+ cells was 0.7 and up to 
4.5 which is consistent with previous results of van Rarenswaay Claasan et al. (11) and 
Toomey et al. (14). 
This wide range of variation in cell infiltration is attributed to different stages of tumors and 
the rate of tumor growth. The activity of macrophages was studied by using CD16+ and HLA-
DR+ markers. In stage II of breast cancer the CD16 and HLA-DR bearing macrophages de-
creased remarkably (Table 3) and this may confirm suppression of tumor infiltrating immune 
cells (5). 
Solid tumors, both primary lesions and metastases, become infiltrated by large numbers of 
tumor-associated leukocytes. These are heterogeneous populations of cells consisting of vari-
ous (and variable) subsets of T cells (helper, suppressor and cytotoxic), B cells, natural killer 
(NK) cells, and macrophages (11). However, the biological relevance and clinical significance 
of these different cellular infiltrates remains the subject of conflicting reports and continuing 
debate. In view of their normally defensive and beneficial role in vivo, leukocytes infiltrating 
tumor were originally believed to herald an immune response to the growing neoplasm. One 
of the first direct indications that killing of tumor cells by macrophages involved direct con-
tact between them and tumor cells was provided by Bucana et al. (15). They produced mor-
phological evidence on translocation of lysosomal organelles from cytotoxic macrophages 
into the cytoplasm of target cells. Electron microscopic observations have shown that destruc-
tion of tumor cells by activated macrophages is a non-phagocytic, lytic process (15). It is re-
ported that the interaction between activated macrophages and the neoplastic cells involves 
intimate cellular binding, is temperature dependent and requires viable, metabolically active 
effectors cells (16). Recently co-cultivation of tumor cells with macrophages has been shown 
to enhance invasiveness of malignant cells in a TNF-alpha dependent manner (17). However, 
the spontaneous regression of an established tumor is a rare event, suggesting that in progres-
sively growing tumors, the immunocompetence and anti-cancer effects of these cells within 
the tumor cell milieu may be compromised. Moreover, subpopulations of associated-
associated leukocytes have been shown to be detrimental to the host and beneficial to progres-
sive tumor growth (12,14). 
It is possible that stimulation of the activity of macrophages can help us in increasing the 
binding of activated macrophages to tumor cells and selectively increase cytolysis of the tu-
mor cells. 
 
Tumor associated macrophages in breast carcinoma 
 
IJI VOL. 2 NO. 2 Spring 2005 122
REFERENCES 
 
1. Remedi MM, Hliba E, Demarchi M, Depiante-Depaoli M. Relationship between immune state and tumor 
growth rate in rats bearing progressive and non-progressive mammary tumors. Cancer Immunol Immunother. 
1998;46:350-4. 
2. Nath D, Hartnell A, Happerfield L, Miles DW, Burchell J, Taylor-Papadimitriou J et al. Macrophage-tumour 
cell interac-tions: identification of MUC1 on breast cancer cells as a potential counter-receptor for the macro-
phage-restricted receptor, sialoadhesin. Immunology. 1999;98:213-9. 
3. Bell D, Chomarat P, Broyles D, Netto G, Harb GM, Lebecque S et al. In breast carcinoma tissue, immature 
dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp 
Med. 1999;190:1417-26. 
4. Lin EY, Pollard JW. Macrophages: modulators of breast cancer progression. Novartis Found Symp. 
2004;256:158-68. 
5. al-Sarireh B, Eremin O. Tumour-associated macrophages (TAMS): disordered function, immune suppression 
and pro-gressive tumour growth. J R Coll Surg Edinb. 2000;45:1-16.  
6. Hildenbrand R, Jansen C, Wolf G, Bohme B, Berger S, von Minckwitz G et al. Transforming growth factor-
beta stimu-lates urokinase expression in tumor-associated macrophages of the breast. Lab Invest. 1998;78:59-71. 
7. Merendino RA, Gangemi S, Misefari A, Arena A, Capozza AB, Chillemi S et al. Interleukin-12 and inter-
leukin-10 pro-duction by mononuclear phagocytic cells from breast cancer patients. Immunol Lett. 1999;68:355-
8. 
8. Lal RB, Edison LJ, Chused TM. Fixation and long-term storage of human lymphocytes for surface marker 
analysis by flow cytometry. Cytometry. 1988;9:213-9. 
9. Wong PY, Staren ED, Tereshkova N, Braun DP. Functional analysis of tumor-infiltrating leukocytes in 
breast cancer patients. J Surg Res. 1998;76:95-103. 
10. O'Sullivan C, Lewis CE. Tumour-associated leucocytes: friends or foes in breast carcinoma. J Pathol. 
1994;172:229-35. 
11. van Ravenswaay Claasen HH, Kluin PM, Fleuren GJ. Tumor infiltrating cells in human cancer. On the possi-
ble role of CD16+ macrophages in antitumor cytotoxicity. Lab Invest. 1992;67:166-74. 
12. Toomey D, Harmey J, Condron C, Kay E, Bouchier-Hayes D. Phenotyping of immune cell infiltrates in 
breast and colo-rectal tumours. Immunol Invest. 1999;28:29-41. 
13. Brunda MJ, Sulich V, Wright RB, Palleroni AV. Tumoricidal activity and cytokine secretion by tumor-
infiltrating macrophages. Int J Cancer. 1991;48:704-8. 
14. O'Sullivan C, Lewis CE, Harris AL, McGee JO. Secretion of epidermal growth factor by macrophages asso-
ciated with breast carcinoma. Lancet. 1993;342:148-9. 
15. Bucana C, Hoyer LC, Hobbs B, Breesman S, McDaniel M, Hanna MG Jr. Morphological evidence for the 
translocation of lysosomal organelles from cytotoxic macrophages into the cytoplasm of tumor target cells. Can-
cer Res. 1976;36:4444-58. 
16. Marino PA, Adams DO. Interaction of Bacillus Calmette--Guerin-activated macrophages and neoplastic cells 
in vitro. I. Conditions of binding and its selectivity. Cell Immunol. 1980;54:11-25. 
17. Hagemann T, Robinson SC, Schulz M, Trumper L, Balkwill FR, Binder C. Enhanced invasiveness of breast 
cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix 
metalloproteases. Car-cinogenesis. 2004;25:1543-9. 
